dc.creator | Ramírez D. | |
dc.creator | Bedoya M. | |
dc.creator | Kiper A.K. | |
dc.creator | Rinné S. | |
dc.creator | Morales-Navarro S. | |
dc.creator | Hernández-Rodríguez E.W. | |
dc.creator | Sepúlveda F.V. | |
dc.creator | Decher N. | |
dc.creator | González W. | |
dc.date.accessioned | 2020-09-02T22:26:31Z | |
dc.date.accessioned | 2022-11-08T20:18:15Z | |
dc.date.available | 2020-09-02T22:26:31Z | |
dc.date.available | 2022-11-08T20:18:15Z | |
dc.date.created | 2020-09-02T22:26:31Z | |
dc.date.issued | 2019 | |
dc.identifier | 20, 9, - | |
dc.identifier | 16616596 | |
dc.identifier | https://hdl.handle.net/20.500.12728/5947 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5142643 | |
dc.language | en | |
dc.publisher | MDPI AG | |
dc.subject | 5,6,7,8 tetrahydropyrido[4,3-d]pyrimidine derivatives | |
dc.subject | Drug-protein interaction | |
dc.subject | Molecular docking | |
dc.subject | Molecular dynamics | |
dc.subject | Mutagenesis screen | |
dc.subject | Pk-thpp | |
dc.subject | Task channels blockers | |
dc.subject | TASK-3 channel | |
dc.subject | 5,6,7,8 tetrahydropyrido [4,3 d] pyrimidine | |
dc.subject | neurotransmitter | |
dc.subject | potassium channel blocking agent | |
dc.subject | pyrimidine derivative | |
dc.subject | task 3 channel | |
dc.subject | threonine | |
dc.subject | unclassified drug | |
dc.subject | KCNK9 protein, human | |
dc.subject | potassium channel blocking agent | |
dc.subject | protein binding | |
dc.subject | pyridine derivative | |
dc.subject | pyrimidine derivative | |
dc.subject | tandem pore domain potassium channel | |
dc.subject | tetrahydropyrido(4,3-d)pyrimidine | |
dc.subject | Article | |
dc.subject | binding affinity | |
dc.subject | binding site | |
dc.subject | chemical interaction | |
dc.subject | conformational transition | |
dc.subject | drug binding site | |
dc.subject | electrophysiology | |
dc.subject | entropy | |
dc.subject | fenestration | |
dc.subject | hydrogen bond | |
dc.subject | IC50 | |
dc.subject | lipophilicity | |
dc.subject | membrane potential | |
dc.subject | molecular docking | |
dc.subject | molecular dynamics | |
dc.subject | molecular mechanics | |
dc.subject | mutagenesis | |
dc.subject | nonhuman | |
dc.subject | pharmacophore | |
dc.subject | protein interaction | |
dc.subject | receptor binding | |
dc.subject | relative binding affinity | |
dc.subject | sequence alignment | |
dc.subject | steady state | |
dc.subject | structure activity relation | |
dc.subject | structure analysis | |
dc.subject | two dimensional quantitative structure activity relationship | |
dc.subject | Xenopus laevis | |
dc.subject | animal | |
dc.subject | antagonists and inhibitors | |
dc.subject | chemistry | |
dc.subject | human | |
dc.subject | molecular docking | |
dc.subject | Xenopus | |
dc.subject | Animals | |
dc.subject | Binding Sites | |
dc.subject | Humans | |
dc.subject | Molecular Docking Simulation | |
dc.subject | Potassium Channel Blockers | |
dc.subject | Potassium Channels, Tandem Pore Domain | |
dc.subject | Protein Binding | |
dc.subject | Pyridines | |
dc.subject | Pyrimidines | |
dc.subject | Xenopus | |
dc.title | Structure/activity analysis of task-3 channel antagonists based on a 5,6,7,8 tetrahydropyrido[4,3-d]pyrimidine | |
dc.type | Article | |